Bruno Chauffert

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.8K citations · Full text

Medicine, Oncology, Pharmacology +13

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

François Ghiringhelli, Cédric Menard, Pierre E. Puig et al. · Cancer Immunology Immunotherapy · 2006 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17

Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells

Fanny Chalmin, Sylvain Ladoire, Grégoire Mignot et al. · Journal of Clinical Investigation · 2010 · 987 citations · Full text

Medicine, Immunology, Oncology +16

CD4⁺CD25⁺ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

François Ghiringhelli, Nicolas Larmonier, E. Schmitt et al. · European Journal of Immunology · 2004 · 868 citations

Life Sciences, Immunology, Oncology +17